awmsg logo



telavancin (Vibativ®)


Reference No. 719

Publication date:
09/01/2012


Appraisal information

telavancin (Vibativ®) 250 mg powder for concentrate for solution for infusion
telavancin (Vibativ®) 750 mg powder for concentrate for solution for infusion


Company: Clinigen Group Plc
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/01/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, telavancin (Vibativ®) cannot be endorsed for use within NHS Wales for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA).
Statement of Advice (SOA)
Download